A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis. Issue 4 (3rd March 2017)

• Record Type: Journal Article
• Authors: Langford, Carol A.; Cuthbertson, David; Ytterberg, Steven R.; Khalidi, Nader; Monach, Paul A.; Carette, Simon; Seo, Philip; Moreland, Larry W.; Weisman, Michael; Koening, Curry L.; Sreih, Antoine G.; Spiera, Robert; McAlear, Carol A.; Warrington, Kenneth J.; Pagnoux, Christian; McKinnon, Kathleen; Forbess, Lindsy J.; Hoffman, Gary S.; Borchin, Renée; Krischer, Jeffrey P.; Merkel, Peter A.
• Other Names: Hajj‐Ali Rula investigator.; Tuthill Katherine investigator.; Gartner Kathleen investigator.; Madden Leah investigator.; Matteson Eric L. investigator.; Kermani Tanaz investigator.; Jaquith Jane investigator.; Amudala Naomi investigator.; Clark‐Cotton Manuella investigator.; Messier Sandra investigator.; Farquharson Julia investigator.; Jagadeesh Samyukta investigator.; McBride Dawn investigator.; Venuturupalli Swamy investigator.; Wallace Daniel investigator.; Phan Richard investigator.; Verde Nadia investigator.; Salinas Denise investigator.; Godina Jennifer investigator.; Davids Morgana investigator.; Udeh Uzunma investigator.; Sejismundo Lourdes investigator.; Harris Jennifer investigator.
• Is Part Of: Arthritis & rheumatology. Volume 69:Issue 4(2017)
• Page Start: 837
• Page End: 845
• Publication Date: 2017-03-03
• Subjects: Arthritis -- Periodicals; Rheumatism -- Periodicals; 616.72
• DOI: 10.1002/art.40044
• Languages: English
• ISSNs: 2326-5191

Abstract

Abstract : Objective: To compare the efficacy of abatacept to that of placebo for the treatment of giant cell arteritis (GCA). Methods: In this multicenter trial, patients with newly diagnosed or relapsing GCA were treated with abatacept 10 mg/kg intravenously on days 1, 15, and 29 and week 8, together with prednisone administered daily. At week 12, patients in remission underwent a double‐blinded randomization to continue to receive abatacept monthly or switch to placebo. Patients in both study arms received a standardized prednisone taper, with discontinuation of prednisone at week 28. All patients remained on their randomized assignment until meeting criteria for early termination or until 12 months after enrollment of the last patient. The primary end point was duration of remission (relapse‐free survival rate). Results: Forty‐nine eligible patients with GCA were enrolled and treated with prednisone and abatacept; of these, 41 reached the week 12 randomization and underwent a blinded randomization to receive abatacept or placebo. Prednisone was tapered using a standardized schedule, reaching a daily dosage of 20 mg at week 12 with discontinuation in all patients at week 28. The relapse‐free survival rate at 12 months was 48% for those receiving abatacept and 31% for those receiving placebo ( P = 0.049). A longer median duration of remission was seen in those receiving abatacept compared to those receiving placebo (median duration 9.9 months versus 3.9 months; P = 0.023). There was no difference in the frequency or severity of adverse events, including infection, between the treatment arms. Conclusion: In patients with GCA, the addition of abatacept to a treatment regimen with prednisone reduced the risk of relapse and was not associated with a higher rate of toxicity compared to prednisone alone.